Unburdening Vision:
A New Therapeutic Future
| Indication | Developmental stage | Transgene | Injection route | Serotype |
|---|---|---|---|---|
| Wet AMD | Clinical Development (Phase 1/2a) | Aflibercept | Subretinal Injection | AAV8 |
NG101 is an investigational gene therapy engineered to overcome the fundamental challenges of current wet AMD treatments. It directly addresses the heavy treatment burden of frequent injections and the fluctuating protein levels that can leave the disease uncontrolled between doses.
Our single-administration approach provides durable, continuous therapeutic expression, eliminating the "peaks and troughs" of intermittent injections for constant disease suppression. Central to this design is a low vector dose, optimized for robust efficacy and a favorable safety profile. This positions NG101 with best-in-class potential for a broad population, including heavily treated patients. (NCT05984927) Learn More on ClinicalTrials.gov
About wet AMD
Wet Age-related Macular Degeneration is a primary cause of irreversible blindness, driven by the pathological overexpression of VEGF. This triggers choroidal neovascularization, causing fluid accumulation and structural damage that leads to progressive central vision loss.
The Challenge of Current Therapies
The standard of care—intravitreal anti-VEGF injections—requires a lifelong, high-frequency regimen. This demanding schedule creates significant treatment burden, often leading to poor compliance and under-treatment. Fluctuating therapeutic levels between injections can cause disease reactivation, highlighting a critical unmet need for continuous disease suppression.
Our Approach: NG101
NG101 is an investigational gene therapy designed to establish a new treatment paradigm for wet AMD. Following a single subretinal injection, NG101 leverages a clinically validated AAV vector to enable continuous, endogenous expression of a potent anti-VEGF protein directly from the retina itself.
By maintaining stable therapeutic protein levels from a single administration, NG101 is engineered to deliver durable disease control while substantially reducing the burden of chronic intravitreal injections. Optimized for high efficacy at a low vector dose — a design choice intended to minimize dose-related inflammation and other adverse events — NG101 aims to offer lasting vision protection and fundamentally transform the management of wet AMD.
